
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States
Keywords: Vaccine; Vaccination; Herpes zoster; Public health impact; Cost-effectiveness; ACIP; Advisory Committee on Immunization Practices; AEs; adverse events; DSA; deterministic sensitivity analysis; HZ; shingles, Herpes zoster; RZV; Adjuvanted Recombinant Zoste